KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.90

Long-Term Transfusion Independence with Luspatercept Versus Epoetin Alfa in Erythropoiesis-Stimulating Agent-Naive, Lower-Risk Myelodysplastic Syndromes in the COMMANDS Trial.

Guillermo Garcia-Manero, Valeria Santini, Amer M Zeidan, Rami S Komrokji, Veronika Pozharskaya, Shelonitda Rose, Karen Keeperman, Yinzhi Lai, Sameer Kalsekar, Barkha Aggarwal, Dimana Miteva, David Valcárcel, Pierre Fenaux, Jake Shortt, Matteo Giovanni Della Porta, Uwe Platzbecker

Adv Ther 42(7) 3576-3589

PMID40377899
PMCIDPMC12182481
DOI10.1007/s12325-025-03208-5
发表日期2025-05-16
入排依据:The study meets criteria for oncology, human, randomized, phase III, and drug intervention. However, it is excluded because the primary/key secondary efficacy endpoint (red blood cell transfusion independence) is not a recognized time-to-event endpoint (OS, PFS, DFS, EFS, RFS, TTP). The results present response rates and cumulative duration, not a Kaplan-Meier survival curve or hazard ratio.
已检查 4 张 PubMed Figure,均未识别为 KM 图:Fig. 1:AI 判定为 other;Fig. 2:森林图/亚组分析图;Fig. 3:AI 判定为 other;Fig. 4:AI 判定为 other。
摘要

摘要

INTRODUCTION: The efficacy of erythropoiesis-stimulating agents (ESAs) for transfusion-dependent (TD) anemia in lower-risk myelodysplastic syndromes (LR-MDS) is limited. Luspatercept achieved significantly greater rates of red blood cell (RBC) transfusion independence (TI) versus epoetin alfa (an ESA) in the phase 3 COMMANDS trial. This analysis assessed long-term RBC-TI, cumulative response, and safety with luspatercept in COMMANDS. METHODS: Eligible patients aged ≥ 18 years, with ESA-naive, RBC TD LR-MDS were randomized 1:1 to receive luspatercept (1.0 mg/kg, titration to 1.75 mg/kg permitted) or epoetin alfa (450 IU/kg, titration to 1050 IU/kg). Disease assessment was carried out at week 24 (day 169) and every 24 weeks thereafter. Treatment continued until disease progression, lack of clinical benefit, unacceptable toxicity, or consent withdrawal. RESULTS: At data cutoff (September 22, 2023; median follow-up: luspatercept 21.4 months, epoetin alfa 20.3 months), a greater proportion of patients treated with luspatercept (n = 182) versus epoetin alfa (n = 181) achieved a longest single RBC-TI period ≥ 1 year (44.5% vs. 27.6%; P = 0.0003) and ≥ 1.5 years (30.2% vs. 13.8%; P < 0.0001). Higher rates of RBC-TI ≥ 1.5 years with luspatercept over epoetin alfa were consistent across all prespecified subgroups, including patients with ring sideroblast-negative status and low baseline serum erythropoietin. Longer cumulative RBC-TI response [sum of all durations of RBC-TI for ≥ 12 weeks; week 1 to end of treatment (95% CI)] was observed with luspatercept [154.7 weeks (118.4-NR)] versus epoetin alfa [91.1 weeks (73.1-123.9)]. Rates of treatment-emergent adverse events, including asthenia and hypertension, generally decreased over time in both arms. Progression rates to high-risk MDS and acute myeloid leukemia were similarly low (< 5%) in both treatment arms. CONCLUSIONS: These data demonstrated sustained, durable clinical benefit across subgroups and support luspatercept as the treatment of choice for anemia in patients with LR-MDS who are TD and ESA-naive. TRIAL REGISTRATION NUMBER: NCT03682536.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(4,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Fig. 1Fig. 1 Long-term RBC-TI responses. EOT end of treatment, RBC-TI red blood cell transfusion-independent. © American Society of Hematology (2024). Reused with permission
非 KM Figure
Fig. 2Fig. 2 Continuous RBC-TI ≥ 1.5 years across patient subgroups. Continuous response defined as patients achieving a single, uninterrupted period of RBC-TI for ≥ 1.5 years from week 1 to end of treatment. CI confidence interval, EPO erythropoietin, SF3B1 splicing factor 3B subunit 1, RBC red blood cell; RBC-TI red blood cell transfusion-independence, RS ring sideroblast. © American Society of Hematology (2024). Reused with permission
非 KM Figure
Fig. 3Fig. 3 Patients with multiple consecutive RBC-TI periods. Multiple periods of RBC-TI ≥ 12 weeks for individual patients are shown in the plot interrupted by evaluation periods or RBC transfusion events. Continuous response defined as patients achieving a single, uninterrupted period of RBC-TI for ≥ 1.5 years from week 1 to end of treatment. RBC red blood cell, RBC-TI red blood cell transfusion-independence. © American Society of Hematology (2024). Reused with permission
非 KM Figure
Fig. 4Fig. 4 Patients with ≥ 1 TEAE or suspected-related TEAE ( A ), ≥ 1 grade 3/4 TEAE or serious TEAE ( B ), ≥ 1 EOI of asthenia or hypertension ( C ) up to 1.5 years. a No reported grade 3/4 TEAEs in weeks 25–36 in the epoetin alfa arm. b No reported grade 3/4 TEAEs in weeks 37–48 in the epoetin alfa arm. c No reported grade 3/4 TEAEs in weeks 61–84 in the epoetin alfa arm. d EOI of asthenia included fatigue, malaise, and lethargy. e EOI of hypertension included hypertension, essential hypertension, hypertensive urgency, labile hypertension, and hypertensive nephropathy. f No reported EOIs of hypertension in weeks 61–72 in the epoetin alfa arm. g No reported EOIs of hypertension in weeks 73–84 in either. EOI event of interest, TEAE treatment-emergent adverse event. © American Society of Hematology (2024). Reused with permission
非 KM Figure